Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.51 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
| ▸ | BMP1 | P13497 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540559 | 0.90 | LPAR1 (0.56) | TAS2R14LPAR1LPAR5BMP1 | |
| SCHEMBL6539996 | 0.86 | HTR6 (0.51) | TAS2R14HTR6 | |
| SCHEMBL6539946 | 0.82 | OPRK1 (0.51) | HTR6 | |
| SCHEMBL6541428 | 0.82 | L3MBTL1 (0.58) | TAS2R14LPAR1TP53TSHRALDH1A1 | |
| SCHEMBL5127211 | 0.81 | CYP26B1 (0.54) | MMP3BMP1HTR6ALDH1A1NPSR1 | |
| SCHEMBL6541013 | 0.80 | CA12 (0.50) | HTR6 | |
| SCHEMBL6540329 | 0.79 | TAS2R14 (0.54) | TAS2R14LPAR1LPAR5MMP3PTGES | |
| SCHEMBL6541221 | 0.79 | LPAR1 (0.52) | LPAR1LPAR5PTGES | |
| SCHEMBL6540146 | 0.78 | LPAR1 (0.52) | TAS2R14LPAR1LPAR5PTGESHTR6 | |
| SCHEMBL6539973 | 0.78 | ALDH1A1 (0.58) | TSHRALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | TAS2R14 3056/4885LPAR1 362/4885LPAR5 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.